Norcliffe Capital Limited
Overview
Norcliffe Capital Limited is a United Kingdom-based family office that operates as a venture capital investor focusing on early-stage companies in the life sciences, MedTech, and biotechnology sectors.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Laverock Therapeutics | Jun 2025 | Seed | Co-investor |
| Biosceptre International Ltd. | Mar 2021 | VC Round | Co-investor |
| Glen Clova Scientific | Apr 2024 | Seed | Lead |
| Santersus AG | Dec 2025 | Series A | Lead |
| Afon Technology | Feb 2023 | Seed | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Norcliffe Capital Limited based?
Norcliffe Capital Limited is headquartered in Edinburgh, United Kingdom.
When was Norcliffe Capital Limited founded?
Norcliffe Capital Limited was founded in 2018.
How many portfolio companies does Norcliffe Capital Limited have?
Norcliffe Capital Limited has 7 portfolio companies in Caplight's dataset.
What are some companies in Norcliffe Capital Limited's portfolio?
Portfolio companies visible on Caplight include Laverock Therapeutics, Biosceptre International Ltd., Glen Clova Scientific, Santersus AG, Afon Technology.
What was Norcliffe Capital Limited's most recent investment shown here?
Norcliffe Capital Limited's most recent investment in this portfolio sample was in Santersus AG in 2025.
What sectors does Norcliffe Capital Limited focus on?
Norcliffe Capital Limited focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech.
What company stages does Norcliffe Capital Limited focus on?
Norcliffe Capital Limited typically invests at the Early stage.